Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study
Conference Paper
-
- Overview
-
- Additional Document Info
-
- View All
-
Overview
publication date
has subject area
published in
presented at event
Additional Document Info
Publisher
start page
end page
volume